Jul. 10 at 1:52 PM
$CRVO
The list is just the current scope around the p38 MAPK inhibitor, meaning CervoMed is primarly strictly focused on brain disorders.
However, a brand new pre-clinical study reveals that their drug mechanism effectively blocks the spinal inflammatory cascade driving severe Sickle Cell Disease (SCD) pain. While still in early-stage in discovery, this breakthrough independent data demonstrates massive untapped potential for CervoMed in the non-opioid pain market - a multi-billion dollar market itself.
Paper from 23th June
https://academic.oup.com/jscd/article/3/Supplement_1/yoag020.003/8714176
